Your browser is no longer supported. Please, upgrade your browser.
FLXN [NASD]
Flexion Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.62 Insider Own2.70% Shs Outstand49.36M Perf Week8.05%
Market Cap479.68M Forward P/E- EPS next Y-0.60 Insider Trans-3.12% Shs Float46.06M Perf Month-20.61%
Income-113.70M PEG- EPS next Q-0.51 Inst Own97.69% Short Float16.82% Perf Quarter-22.31%
Sales85.60M P/S5.60 EPS this Y35.80% Inst Trans0.14% Short Ratio9.15 Perf Half Y-17.25%
Book/sh-0.34 P/B- EPS next Y65.50% ROA-45.90% Target Price- Perf Year7.80%
Cash/sh3.44 P/C2.74 EPS next 5Y20.00% ROE818.80% 52W Range7.52 - 14.39 Perf YTD-18.54%
Dividend- P/FCF- EPS past 5Y-3.20% ROI-45.20% 52W High-33.50% Beta1.48
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin77.50% 52W Low27.26% ATR0.66
Employees257 Current Ratio4.10 Sales Q/Q11.00% Oper. Margin- RSI (14)49.87 Volatility7.97% 7.12%
OptionableYes Debt/Eq- EPS Q/Q54.60% Profit Margin- Rel Volume2.57 Prev Close9.40
ShortableYes LT Debt/Eq- EarningsMar 10 AMC Payout- Avg Volume846.56K Price9.57
Recom1.80 SMA203.26% SMA50-10.99% SMA200-18.01% Volume1,242,828 Change1.81%
Apr-07-21Resumed RBC Capital Mkts Outperform $18
Aug-20-20Initiated Goldman Neutral $15
Jul-31-20Initiated Oppenheimer Outperform $19
Jul-29-20Initiated Credit Suisse Outperform $19
Jun-25-20Initiated H.C. Wainwright Buy $25
May-27-20Initiated Guggenheim Buy $20
Dec-27-19Reiterated The Benchmark Company Buy $19 → $25
Dec-05-19Initiated Craig Hallum Buy
Nov-25-19Initiated BTIG Research Buy $27
May-09-19Upgrade The Benchmark Company Hold → Buy $19
Jan-04-19Reiterated Needham Buy $42 → $36
Jan-04-19Downgrade The Benchmark Company Buy → Hold
Jun-28-18Initiated The Benchmark Company Buy $39
Oct-09-17Reiterated Needham Buy $36 → $42
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Apr-14-21 03:52AM  
Apr-13-21 04:01PM  
Apr-12-21 11:12AM  
Apr-08-21 04:30PM  
Apr-02-21 04:30PM  
Mar-31-21 07:30AM  
Mar-15-21 09:00AM  
Mar-11-21 05:00AM  
Mar-10-21 08:15PM  
04:22PM  
04:01PM  
01:30PM  
Mar-05-21 04:30PM  
Mar-04-21 12:30PM  
Mar-03-21 04:30PM  
Mar-01-21 12:58PM  
07:30AM  
Feb-22-21 04:30PM  
Feb-18-21 02:15PM  
07:30AM  
Feb-01-21 09:00AM  
Jan-13-21 07:00AM  
Jan-07-21 04:30PM  
Dec-21-20 01:03AM  
Dec-16-20 02:16PM  
Dec-07-20 04:30PM  
Dec-04-20 04:30PM  
Nov-06-20 04:30PM  
06:41AM  
Nov-05-20 04:30PM  
08:04AM  
Nov-04-20 06:15PM  
04:33PM  
04:01PM  
Nov-02-20 11:28AM  
Oct-29-20 04:30PM  
12:34PM  
Oct-13-20 06:59AM  
Oct-08-20 04:30PM  
Oct-05-20 09:00AM  
Oct-02-20 04:30PM  
04:30PM  
Sep-21-20 08:37AM  
Sep-09-20 04:30PM  
Sep-08-20 04:30PM  
Sep-04-20 04:30PM  
Sep-03-20 04:30PM  
Aug-20-20 09:51AM  
Aug-19-20 09:00AM  
Aug-07-20 04:30PM  
01:22PM  
Aug-06-20 12:27PM  
Aug-05-20 07:05PM  
04:01PM  
Jul-30-20 04:30PM  
Jul-28-20 12:32PM  
Jul-24-20 06:31AM  
Jul-23-20 12:00PM  
Jul-15-20 09:56AM  
Jul-14-20 06:59AM  
Jul-08-20 12:00PM  
Jul-02-20 08:30AM  
Jun-27-20 01:20PM  
Jun-25-20 10:10AM  
Jun-16-20 04:30PM  
Jun-11-20 05:36PM  
10:23AM  
May-28-20 09:13AM  
May-21-20 12:02PM  
07:30AM  
May-20-20 04:01PM  
May-14-20 09:27AM  
May-13-20 05:00PM  
May-09-20 03:00PM  
May-07-20 04:01PM  
May-05-20 09:00AM  
May-01-20 09:00AM  
Apr-30-20 04:30PM  
Apr-27-20 07:30AM  
Apr-07-20 04:30PM  
Apr-03-20 04:30PM  
Apr-01-20 07:00AM  
Mar-16-20 03:49PM  
Mar-14-20 08:55AM  
Mar-12-20 06:35PM  
04:01PM  
Mar-11-20 04:30PM  
Mar-06-20 04:30PM  
Mar-05-20 12:30PM  
Mar-04-20 04:30PM  
Feb-24-20 04:30PM  
Feb-20-20 12:31PM  
07:12AM  
Feb-07-20 04:30PM  
Jan-28-20 02:36PM  
01:48PM  
Jan-15-20 06:34AM  
Jan-13-20 08:30AM  
Jan-10-20 07:13AM  
Jan-09-20 04:01PM  
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Layman MelissaChief Commercial OfficerMar 15Sale11.804,52053,336103,956Mar 16 05:11 PM
Layman MelissaChief Commercial OfficerJan 28Sale12.552,62432,93188,376Jan 29 08:19 PM
Muzikant AdamChief Business OfficerJan 05Sale11.134,00544,57673,455Jan 07 06:02 PM
KELLEY SCOTTChief Medical OfficerJan 05Sale11.136,82976,007113,549Jan 07 05:58 PM
Wentworth KerryChief Regulatory OfficerJan 05Sale11.136,82976,007113,767Jan 07 05:56 PM
Willwerth ChristinaChief Strategy OfficerJan 05Sale11.136,60273,480115,186Jan 07 05:55 PM
Levine Mark S.General CounselJan 05Sale11.136,82976,007107,431Jan 07 05:52 PM
Arkowitz DavidChief Financial OfficerJan 05Sale11.136,07367,592151,048Jan 07 05:50 PM
MILINAZZO ALANDirectorJul 09Option Exercise2.2018,45040,50022,950Jul 10 04:06 PM
Stejbach MarkDirectorMay 26Buy9.752,05119,9972,051May 27 04:14 PM
Clayman Michael D.President and CEOMay 26Buy9.7510,25699,996346,605May 27 04:11 PM
Arkowitz DavidChief Financial OfficerMay 07Sale10.882,41326,253117,068May 11 04:11 PM